Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Vertex Pharmaceuticals : FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
08/20/2019 | 08:04am EDT

-FDA Grants Priority Review of the application and sets a PDUFA target action date of March 19, 2020-

-Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations-

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen. The FDA has granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 19, 2020. The submission was supported by previously disclosed positive results of two global Phase 3 studies in people with cystic fibrosis (CF): a 24-week Phase 3 study in people with one F508del mutation and one minimal function mutation and a 4-week Phase 3 study in people with two F508del mutations. Both Phase 3 studies showed statistically significant improvements in lung function (percent predicted forced expiratory volume in one second; ppFEV1), which was the primary endpoint, and in all key secondary endpoints. In these studies, the triple combination regimen was generally well tolerated.

"If approved, the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen would be a significant advance in CF treatment as the first CFTR modulator for those with one F508del mutation and one minimal function mutation, and bring additional benefit to patients with two F508del mutations,” said Reshma Kewalramani, M.D., Executive Vice President and Chief Medical Officer at Vertex. "Our goal is to provide medicines that treat the underlying cause of CF to the vast majority of people with CF. We share a sense of urgency with people with CF, caregivers and clinicians to rapidly deliver innovative CF medicines to those waiting, and we look forward to working with the agency as they review the application over the course of the coming months.”

About Cystic Fibrosis
Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinus, sweat gland, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least 1 F508del mutation. These mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.

About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has three approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney diseases.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including nine consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, Dr. Kewalramani's statements in the second paragraph of the press release, the FDA's target action date and information regarding the review process in the United States. While Vertex believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, that regulatory authorities may not approve, or approve on a timely basis, the NDA, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
09/13VERTEX PHARMACEUTICALS : Announces New Access Agreement with Scottish Government..
09/12VERTEX PHARMACEUTICALS : Announces New Access Agreement with Scottish Government..
09/10VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Global Healthcare Conf..
09/03VERTEX PHARMACEUTICALS : to Acquire Semma Therapeutics With a Goal of Developing..
08/21VERTEX PHARMACEUTICALS : FDA Accepts New Drug Application for VX-445, Tezacaftor..
08/20VERTEX PHARMACEUTICALS : FDA Accepts New Drug Application for VX-445 (Elexacafto..
08/01VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
07/31VERTEX : 2Q Earnings Snapshot
07/31VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
07/31VERTEX PHARMACEUTICALS : Reports Second-Quarter 2019 Financial Results
More news
Financials (USD)
Sales 2019 3 700 M
EBIT 2019 1 554 M
Net income 2019 875 M
Finance 2019 3 460 M
Yield 2019 -
P/E ratio 2019 52,9x
P/E ratio 2020 37,8x
EV / Sales2019 11,4x
EV / Sales2020 9,10x
Capitalization 45 783 M
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 213,64  $
Last Close Price 178,12  $
Spread / Highest target 42,6%
Spread / Average Target 19,9%
Spread / Lowest Target 2,74%
EPS Revisions
Lead Independent Director
SVP, Controller & Principal Accounting Officer
Chief Financial Officer & Executive Vice President
Chief Scientific Officer & EVP-Global Research
Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB31.33%13 425